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Abstract
Macrophages are important for the function of the innate immune system, and in solid tumors, they represent a significant
proportion of the tumormass. Tumor-associated macrophages (TAM) have aM2 phenotype and show a multitude of pro-tumoral
functions, promoting tumor cell survival, proliferation, and dissemination. CCL2, synthesized by tumor and stromal cells,
initiates a chemokine cascade inducing these processes. We studied by immunohistochemistry (IHC) the frequency of TAMs
and CCL2 expressing cells in three groups of primary tumor (PT)-recurrence (R) pairs, where relapse was recordedwithin 2 years
(group 1), between 5 and 10 years (group 2), and after 10 years (group 3). In our study all established breast cancers were heavily
infiltrated by CD68 positive cells. Both in PTs and in R lesions the infiltration was more abundant in the peritumoral than in the
intratumoral stroma. The mean frequency ofM2marker and CD14 positive cells in the intratumoral stroma and CCL2 expressing
tumor cells was higher in the Rs as compared to the corresponding PTs. In PTs, a high frequency of CD14 positive cells and a high
expression of CCL2 by tumor cells was associated with an early recurrence. The findings support the current understanding of
immune cell orchestrated development, progression and metastatic spread of breast cancer. Our study showed that a high
frequency of CCL2 positive tumor cells and CD14 positive TAMs are significant risk factors for rapid tumor recurrence.
Potential targets for intervention are discussed.
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Introduction
Macrophages are an important part of the innate immune sys-
tem, and they also participate in tissue remodeling. They have
a non-redundant role in mammary ductal outgrowth during
postnatal mammary gland development [1] via mechanisms
similar to those active during breast tumor progression [2].
Macrophages, with CD68 as the common marker of the cell
lineage, represent a significant proportion of the tumor mass in
solid malignancies. They originate from blood monocytes,
which differentiate into two schematically identified catego-
ries, M1 (classically activated) and M2 (alternatively activat-
ed) [3]. Tumor-associated macrophages (TAM) have the tu-
mor promoting M2 phenotype [4], and this population can
further be divided into M2a, M2b, M2c, and M2d subcate-
gories with different functions [5]. M2c-macrophages, with
CD163 as validated marker, represent the immunosupressive
end of the continuum. Human monocytes and macrophages
also widely express CD14 during migration and differentia-
tion towards CD14 + CD16 ++ non-classical tumor promoting
monocytes [6]. M1 polarized anti-tumor functions harboring
macrophages over express co-stimulatory molecules, such as
CD80 [7–9]. The recruitment of TAM and their interaction
with metastasizing tumor cells is dependent on tumoral and
stromal-derived CCL2, pivotal for the chemokine cascade that
initiates metastatic seeding of breast cancer cells [10–15].
Previously, a high frequency of CD68 positive macro-
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estrogen receptor (ER) and progesterone receptor (PR) nega-
tivity, human epithelial growth factor receptor 2 (HER-2) pos-
itivity, and a basal phenotype [16]. The number of CD163
positive cells in breast tumor samples has been shown to cor-
relate with fast proliferation, poor differentiation, and ER neg-
ativity [17]. The overall frequency of CD68 or CD163 posi-
tive cells in tumor samples has, however, not been shown to
have an independent prognostic significance [18, 19].
In the current study, we examined the frequency and local-
ization of the CD68, CD14, CD206, CD163, and CD80 pos-
itive macrophages in primary breast tumors and the corre-
sponding recurrences, in order to monitor differences between
primary and recurrent tumors, and between early versus late
recurring tumors. We also investigated the expression of
CCL2 to elucidate its role in primary and recurrent tumor
development. Finally, the correlation of the expression of
these markers with the traditional clinicopathological param-
eters was investigated.
Materials and methods
Patients and tissue samples
Paraffin-embedded tissue blocks from primary tumors (PTs)
of 137 patients and their corresponding recurrent (R) lesions
were collected from the archives of the Department of
Pathology, Helsinki University Hospital as described previ-
ously [20]. The primary breast cancer surgery had been con-
ducted in 1974–2006. The cases were selected depending on
the time lapse from the primary operation to the first recur-
rence to represent quick (≤ 2 years), intermediate (5–10 years),
and slow (> 10 years) progressors. All consecutive cases
matching with the required primary treatment-relapse interval
were recruited. They were divided into three groups: Group 1
n = 41, tumors with R within 2 years after primary surgery,
group 2 n = 57, with R after 5–10 years, and group 3 n = 39
with R after > 10 years (range 10 to 23 years). The archival
slides were re-examined, and the histological tumor type and
grade was assigned based on the criteria of Elston and Ellis
[20]. The clinicopathologic characteristics of the patients and
their cancers are summarized in Table 1. The Ethical
Committee of the Helsinki University Central Hospital ap-
proved the study protocol.
Immunohistochemistry
The expression of CD68 and CD14, pan-monocyte/macro-
phage markers, CD163 and CD206,M2macrophagemarkers,
CD80, an M1 macrophage marker, and CCL2, a pivotal
chemokine-associated with macrophage recruiting and matu-
ration, in primary breast cancer and corresponding recurrences
was investigated. The material consisted of early,
intermediate, and late recurring tumors. The grading of the
level of the expression of the selected marker proteins was
based on viewing the entire tumor sections at the × 20 magni-
fication, and specifying the type of the marker positive cells
using × 40 magnification. The method gives a crude estimate
of the frequency of positive cells, not allowing a precise quan-
tification. However, being able to evaluate a large number
(137) of primary tumor/recidive pairs allows confidence on
Table 1 Clinicopathologic parameters of the 137 breast cancer patients
and the site of recurrence
Group 1 n = 41 Group 2 n = 57 Group 3 n = 39
Age at surgery of primary tumor (PT)
< 50 years 19 20 18
≥ 50 years 22 37 21
Tumor size
≥ 20 mm 14 28 24
< 20 mm 26 28 15
system missing 1 1
Lymph node










1 4 7 8
2 22 35 26
3 15 15 5
Histological type
Ductal 24 36 16
Lobular 17 19 23
Special types 0 2 0
Tissue site of recurrence (R)
Skin 6 10 11
Soft tissue 6 12 5
Subcutaneous tissue 12 16 15
Lung 0 4 2
Brain 2 2 0
Lymph node 2 1 2
Ovary 0 1 0
Bone 3 6 4
Liver 5 2 0
Pleura 0 1 0
Peritoneum 2 1 0
Mesenterium 1 0 1
Larynx 1 0 0
Uterus 1 0 1
Duodenum 0 1 0
Note: In group 1, recurrences were detected within 2 years, in group, 2
from 5 to 10 years, and in group 3, > 10 years after primary surgery. Rwas
defined as any local or regional recurrence or any distant metastatic
disease
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the significance of the detected differences in the expression
of the markers. Moreover, the repeatability of the grading,
tested by re-evaluating an aliquot of samples, was 100%.
Inter-individual variation on evaluating the immunohisto-
chemical result of the macrophage phenotype-related
antigenes, CD68, CD14, CD80, CD163, and CD206 and the
macrophage chemo attractant MCP-1/CCL2was negligible,
due to the clarity of the cutting points agreed upon: 0, no
antigen expression; + 1, 5–29% of antigen expressing cells;
+ 2, 30–69% of antigen expressing cells; and + 3, 70–100% of
antigen expressing cells.
For staining result for ER, PR, HER2, and MIB1 the per-
centage of positive stained tumor cells (range 0–100%) was
recorded according to a standard protocol [20]. All tumors
with an over expression of HER2 at protein level (see ref.
20) were tested for HER2 gene amplification by Inform
HER2Dual ISH test (informHER2 dual in situ hybridization).
Immunohistochemical methods and chemicals
Four-m thick sections were deparaffinized in xylene and
rehydrated. Antigen retrieval was done by microwaving in
10 mM citric acid monohydrate for 1 × 5 min at 900 W and
for 3 × 5 min at 600 W. Endogenous peroxidase activity was
blocked by treatment with 0.5% H2O2.
The slides were incubated overnight in a refrigerator at
+4 °C with appropriate dilutions of the primary antibodies.
The same procedure was used for negative controls, omitting
the primary antibody. The reaction was visualized by the Elite
ABC Kit (Vectastain, Vector Laboratories, Burlingame, CA,
USA). As primary antibodies the following reagents were
used: mouse monoclonal clones anti-CD68 PG-M1, dilution
1:200 (DacoCytomation Denmark), anti-CD14 clone 7, dilu-
tion 1:50 (Labb Vision Corporation, USA), anti-CD163 clone
10D6, dilution 1:200 (Leica Biosystems Newcastle Ltd, UK),
anti-CD206 clone 0387, dilution 1:2000 (Atlas Antibodies
AB, Sweden), anti-MCP-1/CCL2 clone 2 dB, dilution
1:5000 (LifeSpan BioSciences, Inc. USA), anti-ERalfa clone
6F11, dilution 1:50 (Novo Castra Newcastle, UK), anti-PR
alfa clone 636, dilution 1:100 (DacoCytomation, Denmark),
anti-HER2 clone CB11, dilution 1:400 (Novo Castra, UK),
anti-Ki67 clone MIB-1, dilution 1:75 (Daco Cytomation,
Denmark), and a rabbit polyclonal antibody anti-CD80 CD/
80/B71, dilution (Sino Biological Inc., P.R. China).
For staining result for ER, PR, HER2, and MIB1, the per-
centage of positive stained tumor cells (range 0–100%) was
analyzed [20]. All tumors with over expression of HER2 at
protein level (2+ and 3+; see ref. 20) were tested for HER2
gene amplification by Inform HER2 Dual ISH test (inform
HER2 dual in situ hybridization). The HER2 gene was
targeted by a dinitrophenyl labeled probe (INFORM HER2
Dual ISH DNA Probe Cocktail, 780-4422, Roche/Ventana/
Tuscon, AZ, USA 780–4422) and visualized with
VENTANA ultraView Silver ISH DNP (SISH) Detection
(760-098, Roche/Ventana/Tuscon, AZ, USA). The chromo-
some 17 centromere was localized with a digoxigenin labeled
probe (INFORMHER2 Dual ISH DNA Probe Cocktail (780-
4422, Roche/Ventana/Tuscon, AZ, USA) and detected using
VENTANA ultraView Red ISH DIG Detection (780-4422,
Roche/Ventana/Tuscon, AZ, USA). The HER2 signals were
seen as black signals and Chr17 as red signals under light
microscope.
Normal human tonsil and placenta tissue were used as pos-
itive controls for macrophage and CCL2 markers, and normal
and malignant breast tissue for the breast epithelium-related
markers. We evaluated the entire tumor area from one repre-
sentative section from the PT and the R. The results were
scored independently by three pathologists (KJ, MH, PH).
Statistical methods
All statistical analyses were performed using SPSS 24.0 for
Windows (SPSS Incorporation, Chicago, IL, USA). The dif-
ferences between the expression of the markers in PTs and the
corresponding Rs within the groups were tested using the
paired samples t test. Kruskal-Wallis test and the Mann-
Whitney U test was used for comparing differences between
the groups. For analyzing the association of the expression of
the markers with the clinicopathologic parameters, ER, PR,
Ki67, and HER2, we used the categorical two-tailed Pearson’s
chi-square test. For Pearson’s chi-square tests the cutoff point
for negativity versus positivity was < + 2 versus ≥ + 2 for
CD68, CD80, CD163, CD206, and CCL2. For ER and PR
the cutoff point for positivity was 1%, and for Ki67 ≥ 14%.
For HER2 only, those tumors with positive gene amplification
were considered positive.
Probability values p < 0.05 were considered significant ex-




In the entire tumor set, the frequency of intratumoral CD68
positive leukocytes was high (≥ 2+) in 46 cases (33.6%) of
PTs and in 43 cases (31.4%) of Rs. The peritumoral stromal
frequency of CD68 positive leukocytes was high (≥ 2+) in 76
cases (55.5%) of PTs and in 73 cases (53.3%) of Rs. The mean
frequency of intratumoral or peritumoral CD68 positive leu-
kocytes did not differ between the PTs and the Rs (P = 0.433,
P = 0.927, Figs. 1–3). The mean frequency of intratumoral
versus peritumoral CD68 positive leukocytes differed signifi-
cantly: the CD68 positive cells were more frequent in the
peritumoral than in intratumoral stroma, P = 0.0001 (data not
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shown). The early relapsing group 1 and the later recurring
groups 2 and 3 did not differ from each other with respect to
the frequency on CD68 positive cells.
The frequency of peritumoral CD68 expressing leukocytes
in PTs correlated positively with ER (P = 0.007) and PR (P =
0.017, Table 2). Both the intratumoral and peritumoral fre-
quency of CD68 expressing leukocytes correlated positively
withMIB1 positivity (≥ 14% as cutoff of positive tumor cells),
(P = 0.016 in both, Table 2).
The frequency of CD68 positive leukocytes did not
correlate with the other clinicopathological parameters:
patient age, axillary lymph node status, tumor size, tu-
mor grade, histological subtype, nor with the HER2 am-
plification status.
Fig. 1 Differences in the mean
frequency of positive cells (0, 1+,
2+, 3+) between the PTs and their
corresponding Rs. *Significant
difference. Paired samples t test
was used
Fig. 2 Differences in the mean frequency of tumor epithelial CCL2,
intratumoral, and peritumoral stromal CD163 and CD14 positive cells
between the PTs and their corresponding Rs in groups 1, 2, and 3.
*Significant difference. Group 1 represents tumors with Rs within
2 years. In group 2, Rs were detected at 5 to 10 years, and in group 3 >
10 years after primary surgery. Paired samples t test was used
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Fig. 3 IHC showing the
expression of DC68, CD14,
CD163, CD206, and CCL2 in
PTs and corresponding residives
(R > 5 years, R > 10 years)
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CD163
The frequency of intratumoral CD163 positive leukocytes in
PTs was high (≥ 2+) in 25 (18.2%) cases and in 34 (24.8%)
cases in Rs. The frequency of peritumoral CD163 positive
leukocytes was high in 103 (75.2%) cases in PTs and in 106
(77.4%) cases in Rs.
The mean frequency of intratumoral CD163 positive cells
was significantly higher in the Rs than in their corresponding
PTs (P = 0.031, Fig. 1–3). The most significant difference was
seen in Group 1 (P = 0.048, Fig. 2). The frequency of the
peritumoral CD163 positive cells did not significantly differ
between the PTs and the Rs, (P = 0.499, Fig. 1).
In the Rs, the frequency of the peritumoral CD163 positive
leukocytes differed between the three groups (P = 0.031,
Kruskal-Wallis test, data not shown). The frequency of
CD163 positive cells was significantly higher in group 2 as
compared to group 1 (P = 0.013, Mann-Whitney U test, data
not shown), but in group 3, the frequency was again at the
same level as in group 1.
The frequency of peritumoral CD163 positive cells was
significantly higher than that of the intratumoral stroma in
both PTs and the Rs, (P = 0.0001), data not shown.
The frequency of peritumoral CD163 positive cells in PTs
correlated positively with MIB1 (P = 0.005) and PR (p =
0.007), Table 2. There was no correlation between CD163
and ER, the prognostic clinicopathological parameters, nor
HER2 amplification.
CD14
The frequency of intratumoral CD14 positive cells was high
(≥ 2+) in 1 (0.7%) PT and in 2 (1.5%) Rs. The frequency of
peritumoral CD14 positive myelo-monocytes was high in 12
(14.6%) PTs and in 39 (28.5%) Rs. The mean frequency of
intratumoral and peritumoral CD14 positive cells was higher
in the R tumors than in their primary counterparts (Fig. 1).
This difference was significant with regard to the peritumoral
cells (P = 0.029, Fig. 1). When analyzing the expression of
CD 14 in the groups 1, 2, and 3, the expression was noted to
Table 2 Relationship between CD68, CD163, CD206, CCL2, CD14, ER, PR, and Ki67 IHC expression, and HER2 gene amplification in PTs of 137
breast cancer patients was investigated and the significant results are shown
Number of cases with low frequency
of intratumoral CD68 positive cells
Number of cases with high frequency
of intratumoral CD68 positive cells
P value
CD68
MIB1 < 14% 44 (71.0%) 18 (29.0%)
MIB1 ≥ 14% 26 (49.1%) 27 (50.9%) 0.016
Number of cases with low frequency
of peritumoral CD68 positive cells
Number of cases with high frequency
of peritumoral CD68 positive cells
ER negative 24 (55.8%) 19 (44.2%)
ER positive 25 (30.9%) 56 (69.1%) 0.007
PR negative 21 (55.3%) 17 (44.7%)
PR positive 28 (32.6%) 58 (67.4%) 0.017
MIB1 < 14% 34 (49.3%) 35 (50.7%)
MIB1 ≥ 14% 15 (27.8%) 39 (72.2%) 0.016
CD163
Number of cases with low frequency
of intratumoral CD163 positive cells
Number of cases with high frequency
of intratumoral CD163 positive cells
P value
HER2ISH negative 68 (73.9%) 24 (26.1%)
HER2ISH positive 14 (100.0%) 0 (0.0%) 0.030
Number of cases with low frequency
of peritumoral CD163 positive cells
Number of cases with high frequency
of peritumoral CD163 positive cells
PR negative 11 (28.9%) 27 (71.1%)
PR positive 8 (9.8%) 74 (90.2%) 0.007
MIB1 < 14% 16 (24.6%) 49 (75.4%)
MIB1 ≥ 14% 3 (5.6%) 51 (94.4%) 0.005
CD14
Number of cases with low frequency
of peritumoral CD14 positive cells
Number of cases with high frequency
of peritumoral CD14 positive cells
P value
MIB1 < 14% 58 (95.1%) 3 (4.9%)
MIB1 ≥ 14% 38 (74.5%) 13 (25.5%) 0.002
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be significantly higher in the peritumoral stroma of the Rs as
compared to PTs in group 3 (P = 0.017, Fig. 1–3). Both
intratumoral and peritumoral frequency of CD14 positive cells
in PTs was the higher the sooner the recurrence happened
(P = 0,031, P = 0,007, Kruskal-Wallis test, data not shown).
In the peritumoral stroma, the difference between groups 1
and 2, and between groups 1 and 3 was significant (P =
0.006, P = 0.016, Mann-Whitney U test, data not shown).
The frequency of neither intratumoral nor peritumoral CD14
positive leukocytes correlated with the prognostic clinicopath-
ological parameters.
CD206
The frequency of intratumoral CD206 positive cells was high
in none of the PTs nor in the Rs. In primary tumors, there were
three cases (3.6%) and in recurrences 5 (3.6%) cases with a
low frequency (1+) of intratumoral CD206 expression. The
frequency of peritumoral CD206 positive cells was high in 4
(2.9%) cases in PTs and in 7 (7.3%) Rs.
The mean frequency of intratumoral CD206 positive leu-
kocytes was significantly higher in the recurrences as com-
pared to the PTs (P = 0.045, Fig. 1–3). The peritumoral posi-
tivity did not differ between the PTs and the Rs. The frequency
of peritumoral CD206 positive cells was significantly higher
than the intratumoral both in PTs and in Rs (P = 0.0001), data
not shown.
There were no significant differences between the groups
in intratumoral nor in peritumoral CD206 positivity.
CD206 positivity did not correlate with the prognostic clin-
icopathological parameters (data not shown).
CD80
There was only a few cases with low frequency of CD80
positive leukocytes in the whole tumor set, and no statistical
analyses were performed.
CCL2/MCP-1
The expression of CCL2 in malignant epithelial cells in PTs
was high (≥ 2+) in 42 cases (30.7%) and the frequency of
stromal CCL2 positive cells in PTs was high in 25 cases
(18.2%). In Rs, CCL2 expression in tumor cells was high in
54 (39.4%), and in stromal cells in 31 (22.6%).
The mean CCL2 expression in tumor epithelial cells was
significantly higher in the Rs compared to the corresponding
PTs (P = 0.024, Figs. 1 and 2). There was no significant dif-
ference in the frequency of CCL2 positive stromal cells be-
tween the PTs and their Rs (P = 0.494, Fig. 1), whereas the
mean tumor epithelial cell expression of CCL2 was signifi-
cantly higher in the Rs than in the PTs in group 3 (P = 0.0001,
Figs. 2 and 3).
The tumor epithelial cell CCL2 positivity was lower in the
PTs in the late relapsing group 3 as compared to the earlier
relapsing groups 1 and 2, although the difference did not reach
statistical significance. The tumor epithelial cell CCL2 posi-
tivity was the higher the earlier the recurrent lesion was diag-
nosed (Fig. 2). CCL2 positivity did not correlate with the
prognostic clinicopathological parameters (data not shown).
Discussion
We screened the expression on CD68 and CD14, pan-mono-
cyte/macrophage markers, CD163 and CD206, M2 macro-
phage markers, CD80, an M1 macrophage marker, and
CCL2, a pivotal chemokine associated with macrophage
recruiting and maturation, in primary breast cancer (primary
tumor, PT) and corresponding recurrences (R). The material
consisted of early, intermediate, and late recurring tumors. The
goal was to evaluate the impact of macrophage infiltration and
M2 maturation on the biological behavior of the tumor, and to
detect potential targets for intervention in patients with breast
cancer.
Pan-macrophage marker positive cells were abundant in all
established tumors, and the infiltration was heavier in the tu-
mor surrounding stroma than in the intratumoral stroma. M2
marker and CD14 positive cells were more frequent in Rs than
in the corresponding PTs. CCL2, the major recruiter of
myeloid-derived macrophages, was also expressed at a higher
rate in Rs than in PTs. Both CCL2 and CD14 showed a ten-
dency of a relatively high expression in those PTs which were
associated with an early recurrence.
It was shown that the CD68 positive cells were more fre-
quent in the peritumoral than in intratumoral stroma. Neither
the PTs and R lesions, nor the different prognostic groups
differed from each other with respect to the expression of
CD68. All established tumors were heavily infiltrated with
CD68 positive cells, which is in accordance with previous
findings. Overall CD68 expression has previously been asso-
ciated with non-favorable features of the tumor, such as ER
negativity and HER2 positivity [16]. In our study the
peritumoral CD68 positivity correlated with ER, suggesting
that the prognostic significance of CD68 positive cells de-
pends on the localization: in non-hypoxic regions macro-
phages tend to maturate towards M1 phenotype, and may in
breast cancer associate with a favorable prognosis. However,
both peritumoral and intratumoral CD68 expression correlated
positively with MIB1 status, which is in accordance with pre-
vious findings suggesting an association of CD68 positive cell
infiltration with tumor aggressivity. In our study, DC68 infil-
tration did not, however, have prognostic significance as mea-
sured by the time of recurrence.
The intratumoral but not the peritumoral frequency of
CD163 positive cells was higher in Rs than in PTs, supporting
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the previous finding that M2 macrophages play an important
role in tumor spread and associate with tumors with features of
poor prognosis [17]. In the Rs, the frequency of the
peritumoral CD163 positive leukocytes seemed to peak in
group 2 (Fig.2), but with lack of further correlation with the
time of recurrence the significance of this finding remains
uncertain.
Only few tumors in our study were positive for CD206,
suggesting that the majority of the M2 macrophages were of
migratory type, which do not express CD206 [21]. The mean
frequency of intratumoral CD206 positive leukocytes was sig-
nificantly higher in the Rs compared to the Pts, which is in
accordance with the concept of macrophage M2 type matura-
tion in tumor microenvironment. Due to the sparse expression,
the impact of the finding remains elusive.
CD80 was expressed in only few tumor samples, which is
in accordance with the understanding that tumor inflitrating
macrophages quite uniformly represent the M2 polarization.
CD14 was more abundantly expressed in the peritumoral
than in the intratumoral stroma. CD14 positive cells were
more abundant in both peritumoral and intratumoral stroma
in those PTs, which were associated with an early R, than in
those, which recurred later. The expression was always higher
in the R than in the corresponding PT. The difference in the
peritumoral infiltration of CD14 positive cells between PTand
R was significant in group 3, where the frequency of CD14
positive cells was relatively low in PTs. In inflammation
monocytes invade tissue by interaction of complementary pair
of CCR2/CCL2 or/and CCR5/CCL5, and the resulting CD14
+ monocyte count increase is a hallmark of human inflamma-
tory disease [22]. CD14 positive TAM population represents a
newly recruited subset of monocytes, and the tumor microen-
vironment directs the newly recruited CCR2 over expressing
CD14++CD16− cells to adopt the tumor promoting interme-
diate or non-classical phenotype. CD14 ++ CD16− mono-
cytes are characterized by an enhanced expression of CCR2,
the cell surface receptor of CCL2 [13]. The frequency of
CD14 positive cells had the same kinetics as the level of
CCL2 expression in tumor cells in our study, suggesting that
the CCL2-pathway effectively recruits CD14 positive mono-
cytes/macrophages, and both CCL2 and CD14 can be seen as
markers of potential tumor spread.
The mean tumor epithelial cell CCL2 expression was sig-
nificantly higher in the Rs compared to the corresponding PTs.
In group 3 (recurrence after 10 years), the increase of the
number of CCL2 positive tumor cells in the R lesions as com-
pared to the corresponding PTs reached statistical signifi-
cance. The mean tumor epithelial cell expression of CCL2 in
the PTs was the higher the earlier the R lesion was diagnosed.
This finding is in accordance with the earlier studies, where an
increased expression of CCL2 in cancer microenvironment
has been shown to be required for tumor progression and
metastasis [23–25]. It has been shown in an experimental
setting, too, that CCL2 together with IL-6 supports the matu-
ration of M2-type macrophages, characterized by the expres-
sion of the plasma membrane receptor CD14 and an increased
expression of mannose receptor CD206 [25], further
underlining the importance of CCL2 in tumor progression.
The co-expression of CCL2 and CD14 may turn out to be
independent prognostic indicators in breast cancer. CCL2 is
also a potential target for intervention.
CCL2 positivity did not correlate with ER, PR, MIB1, and
HER2 amplification nor the other prognostic clinicopatholog-
ical parameters.
The MIB-1 proliferation index has been shown to correlate
directly with tumor size, nodal status, overexpression of p53
and Neu, and the DNA index; and inversely with estrogen and
progesterone receptor status [26]. A low proliferation index
correlates with a longer relapse-free interval and overall sur-
vival. In our study the frequency of peritumoral and
intratumoral CD68 expressing leukocytes and that of
peritumoral CD163 positive cells correlated directly with
MIB-1 expression. This is in accordance with the assumption
that the infiltration of TAM predicts a poor prognosis, al-
though significant correlation was not reached in this study.
Over expression of ERα is a well-established prognostic
factor in breast cancer patients. ERα-positive breast cancers
are associated with a slower tumor growth and a better overall
prognosis. However, the value of ERα status as an indepen-
dent prognostic variable has been diluted by its association
with other prognostic factors and treatment modalities. ER
status may be more important for prognosis in node-negative
cases than in node-positive [27]. In this study, the frequency of
peritumoral but not intratumoral CD68 expressing leukocytes
in PTs correlated positively with ER expression, suggesting
that macrophages specifically in normo-oxic areas may asso-
ciate with tumors with a less aggressive biological behavior.
ER status did not correlate with the other macrophagemarkers
nor CCL2.
The event that initiates the cascade of M2 macrophage
recruitment and maturation is the constitutive IL6-STAT3
pathway activation in cancer cells, and the secretion of
CCL2. Inhibition of myeloid macrophage recruitment and
maturation towards tumor promoting alternatively activated
M2 macrophages is a potential tool in immunologic cancer
care.
Inhibition of the production of CCL2 by trabectedin [28],
allosteric blocking of the function of CCL2 by “Peptide 3,” a
dodecapeptide section of CCL2 [29, 30] and suppressing the
TAM-derived MMP-9 to reduce tumor cell migration and
VEGF activity [31] are examples of successful interventions.
A more downstream inhibition of the CCL2/CCR2 pathway
by blocking CCL3/CCR1 has also been suggested [32].
In this study, the role of the CCL2 pathway in tumor pro-
gression was verified, and the prognostic significance of
CCL2 and CD14 in breast cancer was detected.
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Based on our results, we suggest that the coarse needle
biopsy necessary in diagnosing breast cancer should be cov-
ered by a preventing method due to the risk that it may induce
an unfavorable immunologic reaction and facilitate tumor
metastatic potential via the CCL2 pathway [33]. The possible
benefit of a local intratumoral injection of peptide- or neutral-
izing antibody-based anti-CCL2 agent at the time of biopsy
should be evaluated. Systemic anti-CCL2 treatment as neo-
adjuvant in patients with breast cancer should also be
considered.
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